Drugmaker fights Medicare pricing changes
Taxpayers spend less on a Medicaid prescription for the poor and disabled than they do on the same Medicare prescription for the elderly. So why not save money by having the government pay the same lower Medicaid price for drugs for both programs? That idea was the biggest spending cut proposed in President Barack Obama's deficit-reduction plan. But drug makers such as Eli Lilly and Co. argue that the cut would be a "pretty big body blow," potentially causing job losses and hurting the development of new drugs. Now, when the government buys Lilly's Zyprexa for a Medicare patient, for example, the cost is negotiated between the company and the private insurance provider of the Medicare drug benefit. When the government buys the same anti-psychotic medication for a Medicaid patient, Lilly has to give the government a set rebate.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- 3 Traits Personality Assessments Can't Reveal
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Carondelet to Pay $35M to Settle Fraud Allegations
- CHS Hacked, 4.5M Patient Records Compromised